Log In
Print this Print this

Oncotype DX breast cancer assay

  Manage Alerts
Collapse Summary General Information
Company Genomic Health Inc.
DescriptionDiagnostic assay that analyzes the expression of 21 genes to generate a Recurrence Score (RS) to quantify magnitude of chemotherapy benefit and likelihood of recurrence
Molecular Target Not applicable
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsPredict breast cancer patient's response to chemotherapy; Predict breast cancer recurrence; Predict breast cancer survival; Predict distant recurrence in node-negative and node-positive, hormone receptor-positive breast cancer patients; Predict likelihood of breast cancer recurrence and measure the magnitude of treatment benefit with chemotherapy; Predict the benefit of a standard chemotherapy regimen in node-positive breast cancer; Predict the likelihood of disease recurrence and likelihood of chemotherapy benefit for node-negative, estrogen receptor-positive breast cancer patients; Predict the risk of local recurrence of ductal carcinoma in situ of the breast (DCIS)
Regulatory Designation


NewBridge Pharmaceuticals Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today